Qing Fang

Title: Qing Fang: Innovator in Genetically Modified Animal Models

Introduction

Qing Fang is a notable inventor based in Chappaqua, NY (US). He has made significant contributions to the field of genetic engineering, particularly in the development of animal models that express human proteins. With a total of 2 patents, his work has implications for biomedical research and therapeutic applications.

Latest Patents

Qing Fang's latest patents focus on methods involving genetically modified mice that express human albumin. These patents detail non-human animal genomes, non-human animal cells, and non-human animals that comprise a humanized albumin locus. The methods outlined in these patents allow for the assessment of in vivo efficacy of human-albumin-targeting reagents, such as nuclease agents designed to target human albumin. This innovative approach provides valuable tools for researchers in the field of medicine.

Career Highlights

Throughout his career, Qing Fang has worked with prominent companies in the pharmaceutical industry. He has been associated with Regeneron Pharmaceuticals, Inc. and Regeneran Pharmaceuticals, Inc. His experience in these organizations has contributed to his expertise in genetic engineering and the development of therapeutic models.

Collaborations

Qing Fang has collaborated with several professionals in his field, including Chia-Jen Siao and Dan Chalothorn. These collaborations have likely enhanced his research and development efforts, leading to innovative solutions in genetic engineering.

Conclusion

Qing Fang's work in genetically modified animal models represents a significant advancement in the field of biomedical research. His patents and collaborations highlight his commitment to innovation and the potential impact of his inventions on future therapies.